查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1137008

骨关节炎治疗药市场:各药物类别，各给药途径，各疾病类型，各流通管道，各地区- 规模，占有率，展望，机会分析，2022年～2030年

Osteoarthritis Drugs Market, by Drug Class, by Route of Administration, by Disease Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 231 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场动态

市场的主要参与者专注于收购等有机增长战略，预计这将在预测期内推动全球骨关节炎治疗市场的增长。

本调查的主要特征

  • 本报告提供以2021年为基准年的预测期间（2022-2030 年）之全球骨关节炎治疗药市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
  • 并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
  • 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
  • 并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球骨关节炎治疗药市场的主要参与者之企业简介。
  • 藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 全球骨关节炎治疗药市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以透过全球骨关节炎治疗药市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

目录

第1章 调查目的与前提条件

  • 调查目的
  • 前提条件
  • 简称的说明

第2章 市场展望

  • 报告内容
  • 市场定义和范围
  • 摘要整理
    • 市场明细:各药物类别
    • 市场明细:各给药途径
    • 市场明细，各疾病类型
    • 市场明细:各流通管道
    • 市场明细，各地区
  • 连贯机遇地图(COM)

第3章 市场动态，法规，趋势分析

  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 影响分析
  • 开发平台分析
  • 保险偿付方案
  • 流行病学
  • PEST分析
  • 法律规章情景
  • 新产品的上市
  • 共同研究及契约
  • 市场趋势

第4章 骨关节炎治疗药的全球市场-冠状病毒(COVID-19)疫情的影响

  • 整体影响
  • COVID-19市场的影响

第5章 骨关节炎治疗药的全球市场，各药物类别，2017年～2030年

  • 止痛药
  • 非类固醇消炎剂
  • 皮质类固醇
  • 玻尿酸
  • 阶段III医药品

第6章 骨关节炎治疗药的全球市场(各给药途径):2017年～2030年

  • 口服剂
  • 非口服剂
  • 局部给药

第7章 骨关节炎治疗药的全球市场，各疾病类型，2017年～2030年

  • 脚踝的骨关节炎
  • 变形性髋关节症
  • 变形性膝关节症
  • 变形性肩关节症
  • 其他(脊椎骨关节炎，颈椎骨关节炎)

第8章 骨关节炎治疗药的全球市场(各流通管道):2017年～2030年

  • 医院内药局
  • 零售药局
  • 线上药局

第9章 骨关节炎治疗药的全球市场:各地区，2017年～2030年

  • 北美
  • 美国
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他的南美地区
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 中东地区
  • GCC
  • 以色列
  • 其他的中东地区
  • 非洲
  • 北非
  • 中非
  • 南非

第10章 竞争情形

  • 热图分析
  • 企业简介
    • Pfizer, Inc.
    • Abbott
    • Eli Lilly and Company
    • ABIOGEN PHARMA S.p.A
    • Horizon Therapeutics plc
    • Ferring B.V.
    • Merck Sharp & Dohme Corp.
    • Medivir
    • Bioventus
    • Sanofi
    • Regeneron
    • GlaxoSmithKline Plc.
    • Johnson & Johnson Private Limited
    • Bayer AG
    • Novartis AG
    • Ferring B.V.
    • Pacira Pharmaceuticals, Inc
    • Zimmer Biomet
    • OrthogenRx, Inc.
    • PHARMED LTD

第11章 章节

  • 参考文献
  • 调查手法的介绍
  • 关于出版社
简介目录
Product Code: CMI2580

Osteoporosis is a systemic disorder characterized by decreased bone mass and microarchitectural deterioration of bone tissue, leading to bone fragility and increased susceptibility to fractures of the hip, spine, and wrist. Due to its important prevalence worldwide, osteoporosis is considered a serious public health concern associated with disability and pain. The pathophysiology of osteoporosis is an imbalance between bone resorption and bone formation. In osteoporosis, bone resorption takes place to a greater extent than bone formation, so a negative balance occurs with a net loss of bone and an accompanying increasing risk of fractures, resulting in deformity and chronic pain. Nociceptive pain is considered to be chronic when it has been present for at least 3 months.

  • The imbalance between bone formation and bone resorption might occur as a result of one or a combination of the following factors:
  • Increased bone resorption within a remodeling unit.
  • Decreased bone formation within a remodeling unit (incomplete coupling)

Market Dynamics

Key players in the market are focused on organic growth strategies such as acquisitions, which is expected to drive the global osteoarthritis drugs market growth over the forecast period. For instance, on August 15, 2022, Gurnet Point Capital, an investment service company and Patient Square Capital, a healthcare investment company, announced the completion of their acquisition of Radius Health, Inc., a Biotechnology Company. Radius' lead product, TYMLOS (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. This acquisition will help the company in further expansion in the osteoarthritis drugs market over the forecast period.

However, use of Non-steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and naproxen in pain management of osteoarthritis can cause cardiovascular diseases, which in turn is expected to hinder the market growth. For instance, in June 2018, the European League against Rheumatism (EULAR) stated the risk of cardiovascular diseases with the regular use of NSAIDs in the treatment of osteoarthritis pain.

Key features of the study:

  • This report provides an in-depth analysis of the global osteoarthritis drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 - 2030, considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global osteoarthritis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Pfizer, Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Therapeutics plc, Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Sanofi, Regeneron, GlaxoSmithKline Plc., Johnson & Johnson Private Limited, Bayer AG, Novartis AG, Ferring B.V., Pacira Pharmaceuticals, Inc, Zimmer Biomet, OrthogenRx, Inc. and PHARMED LTD.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future drug launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global osteoarthritis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoarthritis drugs market

Detailed Segmentation:

  • Global Osteoarthritis Drugs Market, By Drug Class:
    • Analgesics
    • Non-steroidal Anti-Inflammatory Drugs
    • Corticosteroids
    • Hyaluronic Acid
    • Phase III Drugs
  • Global Osteoarthritis Drugs Market, By Route of Administration:
    • Oral
    • Parenteral
    • Topical
  • Global Osteoarthritis Drugs Market, By Disease Type:
    • Ankle Osteoarthritis
    • Hip Osteoarthritis
    • Knee Osteoarthritis
    • Shoulder Osteoarthritis
    • Others (Spinal Osteoarthritis and Cervical Osteoarthritis)
  • Global Osteoarthritis Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Osteoarthritis Drugs Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Pfizer Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Abbott
    • Eli Lilly and Company
    • ABIOGEN PHARMA S.p.A
    • Horizon Therapeutics plc
    • Ferring B.V.
    • Merck Sharp & Dohme Corp.
    • Medivir
    • Bioventus
    • Sanofi
    • Regeneron
    • GlaxoSmithKline Plc.
    • Johnson & Johnson Private Limited
    • Bayer AG
    • Novartis AG
    • Ferring B.V.
    • Pacira Pharmaceuticals, Inc
    • Zimmer Biomet
    • OrthogenRx, Inc.
    • PHARMED LTD

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Disease Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Reimbursement Scenario
  • Epidemiology
  • Pest Analysis
  • Regulatory Scenario
  • New Product Launches
  • Collaborations and Agreements
  • Market Trends

4. Global Osteoarthritis Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • COVID-19 Impact on the market

5. Global Osteoarthritis Drugs Market, By Drug Class, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Analgesics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Nonsteroidal Anti-Inflammatory Drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Corticosteroids
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Hyaluronic Acid
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Phase III Drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Osteoarthritis Drugs Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017- 2030
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Parenteral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Topical
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Osteoarthritis Drugs Market, By Disease Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017- 2030
    • Segment Trends
  • Ankle Osteoarthritis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Hip Osteoarthritis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Knee Osteoarthritis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Shoulder Osteoarthritis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others (Spinal Osteoarthritis and Cervical Osteoarthritis)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Osteoarthritis Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million )

9. Global Osteoarthritis Drugs Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Heat Map Analysis
  • Company Profile
    • Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Market Strategies
    • Abbott
    • Eli Lilly and Company
    • ABIOGEN PHARMA S.p.A
    • Horizon Therapeutics plc
    • Ferring B.V.
    • Merck Sharp & Dohme Corp.
    • Medivir
    • Bioventus
    • Sanofi
    • Regeneron
    • GlaxoSmithKline Plc.
    • Johnson & Johnson Private Limited
    • Bayer AG
    • Novartis AG
    • Ferring B.V.
    • Pacira Pharmaceuticals, Inc
    • Zimmer Biomet
    • OrthogenRx, Inc.
    • PHARMED LTD
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About Us